{
    "title": "111_s1315",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Drug Price Competition Act of \n2009''.\n\nSEC. 2. EXCLUSIVITY PERIOD.\n\n    (a) First Applicant.--Section 505(j)(5) of the Federal Food, Drug, \nand Cosmetic Act (21 U.S.C. 355(j)(5)) is amended--\n            (1) in subparagraph (B)(iv)--\n                    (A) in subclause (II), by striking item (bb) and \n                inserting the following:\n                                            ``(bb) First applicant.--As \n                                        used in this subsection, the \n                                        term `first applicant' means--\n\n                                                    ``(AA) an applicant \n                                                that, on the first day \n                                                on which a \n                                                substantially complete \n                                                application containing \n                                                a certification \n                                                described in paragraph \n                                                (2)(A)(vii)(IV) is \n                                                submitted for approval \n                                                of a drug, submits a \n                                                substantially complete \n                                                application that \n                                                contains and lawfully \n                                                maintains a \n                                                certification described \n                                                in paragraph \n                                                (2)(A)(vii)(IV) for the \n                                                drug; or\n\n                                                    ``(BB) an applicant \n                                                for the drug not \n                                                described in item (AA) \n                                                that satisfies the \n                                                requirements of \n                                                subclause (III).''; and\n\n                    (B) by adding at the end the following:\n                                    ``(III) An applicant described in \n                                subclause (II)(bb)(BB) shall--\n                                            ``(aa) submit and lawfully \n                                        maintain a certification \n                                        described in paragraph \n                                        (2)(A)(vii)(IV) or a statement \n                                        described in paragraph \n                                        (2)(A)(viii) for each unexpired \n                                        patent for which a first \n                                        applicant described in item \n                                        (AA) had submitted a \n                                        certification described in \n                                        paragraph (2)(A)(vii)(IV) on \n                                        the first day on which a \n                                        substantially complete \n                                        application containing such a \n                                        certification was submitted;\n                                            ``(bb) with regard to each \n                                        such unexpired patent for which \n                                        the applicant submitted a \n                                        certification described in \n                                        paragraph (2)(A)(vii)(IV), no \n                                        action for patent infringement \n                                        was brought against the \n                                        applicant within the 45-day \n                                        period specified in paragraph \n                                        (5)(B)(iii), or if an action \n                                        was brought within such time \n                                        period, the applicant has \n                                        obtained the decision of a \n                                        court (including a district \n                                        court) that the patent is \n                                        invalid or not infringed \n                                        (including any substantive \n                                        determination that there is no \n                                        cause of action for patent \n                                        infringement or invalidity, and \n                                        including a settlement order or \n                                        consent decree signed and \n                                        entered by the court stating \n                                        that the patent is invalid or \n                                        not infringed); and\n                                            ``(cc) but for the \n                                        effective date of approval \n                                        provisions in subparagraphs (B) \n                                        and (F) and sections 505A and \n                                        527, be eligible to receive \n                                        immediately effective approval \n                                        at a time before any other \n                                        applicant has begun commercial \n                                        marketing.''; and\n            (2) in subparagraph (D)--\n                    (A) in clause (i)(IV), by striking ``The first \n                applicant'' and inserting ``The first applicant, as \n                defined in subparagraph (B)(iv)(II)(bb)(AA),''; and\n                    (B) in clause (iii), in the matter preceding \n                subclause (I)--\n                            (i) by striking ``If all first applicants \n                        forfeit the 180-day exclusivity period under \n                        clause (ii)''; and\n                            (ii) by inserting ``If all first \n                        applicants, as defined in subparagraph \n                        (B)(iv)(II)(bb)(AA), forfeit the 180-day \n                        exclusivity period under clause (ii) at a time \n                        at which no applicant has begun commercial \n                        marketing''.\n    (b) Effective Date and Transitional Provision.--\n            (1) Effective date.--The amendments made by subsection (a) \n        shall be effective only with respect to an application filed \n        under section 505(j) of the Federal Food, Drug, and Cosmetic \n        Act (21 U.S.C. 355(j)) to which the amendments made by section \n        1102(a) of the Medicare Prescription Drug Improvement and \n        Modernization Act of 2003 (Public Law 108-173) apply.\n            (2) Transitional provision.--An application filed under \n        section 505(j) of the Federal Food, Drug, and Cosmetic Act (21 \n        U.S.C. 355(j)), to which the 180-day exclusivity period \n        described in paragraph (5)(iv) of such section does not apply, \n        and that contains a certification under paragraph \n        (2)(A)(vii)(IV) of such Act, shall be regarded as a previous \n        application containing such a certification within the meaning \n        of section 505(j)(5)(B)(iv) of such Act (as in effect before \n        the amendments made by Medicare Prescription Drug Improvement \n        and Modernization Act of 2003 (Public Law 108-173)) if--\n                    (A) no action for infringement of the patent that \n                is the subject of such certification was brought \n                against the applicant within the 45-day period \n                specified in section 505(j)(5)(B)(iii) of the Federal \n                Food, Drug, and Cosmetic Act (21 U.S.C. \n                355(j)(5)(B)(iii)), or if an action was brought within \n                such time period, the applicant has obtained the \n                decision of a court (including a district court) that \n                the patent is invalid or not infringed (including any \n                substantive determination that there is no cause of \n                action for patent infringement or invalidity, and \n                including a settlement order or consent decree signed \n                and entered by the court stating that the patent is \n                invalid or not infringed);\n                    (B) the application is eligible to receive \n                immediately effective approval, but for the effective \n                date of approval provisions in sections 505(j)(5)(B) \n                (as in effect before the amendment made by Public Law \n                108-173), 505(j)(5)(F), 505A, and 527 of the Federal \n                Food, Drug, and Cosmetic Act (21 U.S.C. 355(j)(5)(B), \n                355(j)(5)(F), 355a, 360cc); and\n                    (C) no other applicant has begun commercial \n                marketing."
}